Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Death/hospice 38% Improvement Relative Risk Mechanical ventilation 18% ICU admission 23% c19zinc.com/carlucciz.html Favors zinc Favors control
8 May 2020 - Late treatment study
Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients
Carlucci et al., J. Med. Microbiol., Sep 15, 2020, doi: 10.1099/jmm.0.001250 (preprint 5/8) (Peer Reviewed)
Source   PDF   Share   Tweet
Retrospective 932 patients showing that the addition of zinc to HCQ+AZ reduced mortality / transfer to hospice, ICU admission, and the need for ventilation.
risk of death/hospice, 37.7% lower, RR 0.62, p = 0.002, treatment 54 of 411 (13.1%), control 119 of 521 (22.8%), NNT 10, adjusted per study, odds ratio converted to relative risk, multivariate logistic regression.
risk of mechanical ventilation, 18.0% lower, RR 0.82, p = 0.40, treatment 29 of 411 (7.1%), control 62 of 521 (11.9%), NNT 21, adjusted per study, odds ratio converted to relative risk, multivariate logistic regression.
risk of ICU admission, 23.5% lower, RR 0.77, p = 0.17, treatment 38 of 411 (9.2%), control 82 of 521 (15.7%), NNT 15, adjusted per study, odds ratio converted to relative risk, multivariate logistic regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes.
Carlucci et al., 5/8/2020, retrospective, USA, North America, peer-reviewed, 6 authors.
All Studies   All Outcomes
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Submit